A relationship between meat consumption and how it affects gut bacteria, immune cell profiles, and metabolism was identified in people with relapsing-remitting multiple sclerosis (RRMS) participating in a small study. Specifically, a diet rich in meat was associated with a decrease in Bacteriodes thetaiotaomicron, a common gut bacteria that works…
A novel algorithm that combines genetic, environmental, and clinical data could be useful for predicting whether people with a first onset of multiple sclerosis (MS)-like disease — known as clinically isolated syndrome (CIS) — will experience relapses or a worsening of their disease over time. The…
Multiple sclerosis (MS) is characterized by changes in methylation — a type of chemical modification in the DNA that changes how genes are read — in immune cells called T-cells, according to a new study. The results also suggest that treatments for MS can help to normalize methylation…
Atara Biotherapeutics has reached an agreement with Fujifilm Diosynth Biotechnologies for the production of its cell therapy pipeline, including ATA188, an experimental therapy being investigated for the treatment of progressive multiple sclerosis (MS). Under the agreement, Fujifilm will acquire Atara’s T-Cell Operations and Manufacturing (ATOM) facility in Thousand…
A Phase 2 clinical trial into the safety and tolerability of higher-dose temelimab as a potential therapy for relapsing forms of multiple sclerosis (MS) is now complete, and top-line data is expected by late March, its developer, GeNeuro, announced. The ProTEct-MS Phase 2 trial (NCT04480307), conducted at the Karolinska…
Nearly a third of multiple sclerosis (MS) patients with COVID-19 experience symptoms that last at least one month, according to a review of of more than 550 infected MS patients in the U.K. who did not need to be hospitalized. This study’s rate is higher than that reported for the…
Trigeminal neuralgia, a chronic pain condition characterized by shocks or burning sensations in the face, seems to be much more common among people with multiple sclerosis (MS) than in the general population, according to a review of published studies. This condition also is more prevalent in women with…
ANI Pharmaceuticals has announced the full U.S. commercial availability of Cortrophin Gel (repository corticotropin injection), an injectable therapy approved for managing acute relapses in people with multiple sclerosis (MS) and other autoimmune disorders. “Patients with certain chronic autoimmune conditions often need additional treatment options,” Mary Pao Seideman, MD,…
Adverse childhood experiences (ACEs) did not increase the risk of multiple sclerosis (MS) development and were not associated with worse clinical outcomes, a recent study reported. These findings add to the complexity of the potential relationship between ACEs and MS that has emerged across several research studies. “Our primary…
Multiple sclerosis (MS) patients with weak immune responses to COVID-19 vaccines are more likely to respond successfully to the booster shot if they are receiving an anti-CD20 therapy compared with those on Gilenya (fingolimod), according to a small study in Norway. These early findings suggest that booster shots…
Women with relapsing-remitting multiple sclerosis (RRMS) have more brain lesions and accelerated brain volume loss (BVL) after pregnancy compared with pre-pregnancy measurements, recent data showed. Brain lesions in the early postpartum period — the first months following childbirth — were associated with a higher risk of worsened disability and relapse…
Vitamin D can influence the immune system’s tolerance to certain proteins by changing how DNA is packaged in specific immune cells called dendritic cells, according to a new study. Its findings could have implications for treating diseases like multiple sclerosis (MS) that are characterized by the immune system attacking…
Tevogen Bio is planning to make use of its virus-fighting immune cell technology and turn it against Epstein-Barr virus (EBV), a common virus thought to greatly increase the risk of multiple sclerosis (MS). The technology employs off-the-shelf cytotoxic T-cells — a type of white blood cell that can…
Similarities between an Epstein-Barr virus (EBV) protein and a brain protein called GlialCAM may explain why EBV infection increases the risk of multiple sclerosis (MS), results from a new study show. Due to the structural resemblance of the two proteins, B-cells — a type of immune cell that is critical…
The MS Society of Canada is hosting its annual MS Read-a-Thon, a fundraiser that supports vital services to the multiple sclerosis (MS) community and to disease research while helping children discover the joys of reading. For a 45th year, the program invites children, individually or in teams…
A Kessler Foundation scientist has been awarded nearly $600,000 to support the development and testing of a behavioral therapy intervention aiming to improve quality of life for people with multiple sclerosis (MS). An upcoming clinical trial into the intervention (NCT05195320), expected to begin…
A new imaging technique called magnetic resonance spectroscopic imaging, or MRSI, could be useful for diagnosing and monitoring multiple sclerosis (MS), according to a small study. “If confirmed in longitudinal clinical studies, this new neuroimaging technique could become a standard imaging tool for initial diagnosis, for disease progression and…
Tecfidera (dimethyl fumarate) appears to have similar benefits to Gilenya (fingolimod) in preventing relapses and the loss of motor function and cognition in people with multiple sclerosis (MS), a study with real-world data found. The two medications also led to similar findings on MRI scans, including in…
Exergames — playing video games that involve physical exercise — may be more effective at improving balance in people with multiple sclerosis (MS) than conventional rehabilitation, a review of current studies suggested. The study, “Efficacy of Virtual Reality and Exergaming in Improving Balance in Patients With…
Cyxone will work with a European organization to scale up production of the active ingredient in T20K, its experimental treatment for multiple sclerosis (MS), the company announced. The collaboration, which will cover the development of a new manufacturing method and later the…
Differences in the physical architecture of the brain may explain why some people with multiple sclerosis (MS), but not others, experience a placebo effect, according to a new study. The results suggest that MS itself may make some individuals unable to experience the benefits of a placebo. “Our findings…
Acthar Gel (repository corticotropin injection) may be useful for managing disease relapses in people with relapsing-remitting multiple sclerosis (RRMS) who fail to respond to treatment with corticosteroids, according to results from a small clinical trial. The study, “Results from a multicenter, randomized, double-blind, placebo-controlled study…
It took some time for Tyler Campbell to truly accept he had relapsing-remitting multiple sclerosis. The San Diego State University running back had just finished his junior year in 2007 when his multiple sclerosis (MS) symptoms began. After an MRI confirmed the diagnosis, his neurologist cleared him to…
Long-term treatment with Gilenya (fingolimod) in routine clinical practice is safe and effective for relapsing-remitting multiple sclerosis (RRMS), a five-year study in Germany of more than 4,000 patients reported. Over time, relapses in the majority of study patients who continued with Gilenya became less common and less severe,…
Under rules in the No Surprises Act, insured patients people in the U.S., including those with multiple sclerosis, should no longer receive unexpected medical bills for emergency care or for treatment from out-of-network providers at facilities in their network. The act, which became effective on Jan. 1, prohibits…
The ENSURE-2 Phase 3 clinical trial, evaluating Immunic Therapeutics’ experimental oral therapy IMU-838 (vidofludimus calcium) in adults with relapsing-remitting multiple sclerosis (RRMS), has enrolled its first patient. The milestone, announced in an email to Multiple Sclerosis News Today, follows the recruitment of the first RRMS patient in…
Infection with the common Epstein-Barr virus (EBV) increases the risk of developing multiple sclerosis (MS) by 32 times — the strongest link yet — according to a study looking at two decades of data from more than 10 million U.S. military members. “The hypothesis that EBV causes MS has been…
Emerald Health Pharmaceuticals will soon begin enrollment in a Phase 2a clinical trial investigating its cannabidiol-derived therapy EHP-101 in relapsing forms of multiple sclerosis (MS). The trial (NCT04909502) aims to recruit 50 patients, ages 18-55, with relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).
Among people with multiple sclerosis (MS), a progressive disease type and the use of anti-CD20 therapies — such as ocrelizumab and rituximab — were associated with an increased risk of death from COVID-19, a new meta-analysis revealed. “We hope that these findings … may help neurologists in optimizing…
Atara Biotherapeutics has partnered with Imeka to use its proprietary biomarker imaging technology in the ongoing EMBOLD Phase 2 clinical trial, which is investigating ATA188 for the treatment of progressive forms of multiple sclerosis (MS). The imaging technology will be used to determine if Atara’s ATA188…
Get regular updates to your inbox.
